<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Isotretinoin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00982</strong>&#160; (APRD00140)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Isotretinoin is a medication used for the treatment of severe acne. It is sometimes used in prevention of certain skin cancers. It is a retinoid, meaning it derives from vitamin A and is found in small quantities naturally in the body. Isotretinoin binds to and activates nuclear retinoic acid receptors (<span class="caps">RAR</span>), thereby regulating cell proliferation and differentiation. This agent also exhibits immunomodulatory and anti-inflammatory responses and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00982/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00982/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00982.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00982.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00982.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00982.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00982.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00982">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Absorica</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Accutane Roche</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Myorisan</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>ZENATANE</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-acne-preparations">Anti-acne preparations</a></li>
<li><a href="/mesh/skin-and-mucous-membrane-agents">Skin and Mucous Membrane Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>4759-48-2</td></tr><tr><th>Weight</th><td>Average: 300.4351<br>Monoisotopic: 300.20893014</td></tr><tr><th>Chemical Formula</th><td>C<sub>20</sub>H<sub>28</sub>O<sub>2</sub></td></tr><tr><th>InChI Key</th><td>SHGAZHPCJJPHSC-XFYACQKRSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14-</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Lipids</td></tr><tr><th>Class</th><td>Prenol Lipids</td></tr><tr><th>Subclass</th><td>Retinoids</td></tr><tr><th>Direct parent</th><td>Retinoids</td></tr><tr><th>Alternative parents</th><td>Diterpenes; Carbocyclic Fatty Acids; Branched Fatty Acids; Unsaturated Fatty Acids; Enones; Carboxylic Acids; Polyamines; Enolates</td></tr><tr><th>Substituents</th><td>enone; enolate; polyamine; carboxylic acid; carboxylic acid derivative</td></tr><tr><th>Classification description</th><td>This compound belongs to the retinoids. These are compounds that are related to vitamin A, especially retinol.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of severe recalcitrant nodular acne</td></tr><tr><th>Pharmacodynamics</th><td>Isotretinoin, a retinoid, is indicated in the treatment of severe recalcitrant nodular acne. Nodules are inflammatory lesions with a diameter of 5 mm or greater. The nodules may become suppurative or hemorrhagic. "Severe," by definition, means "many" as opposed to "few or several" nodules. Clinical improvement in nodular acne patients occurs in association with a reduction in sebum secretion. The decrease in sebum secretion is temporary and is related to the dose and duration of treatment with Accutane, and reflects a reduction in sebaceous gland size and an inhibition of sebaceous gland differentiation.</td></tr><tr><th>Mechanism of action</th><td>Isotretinoin noticeably reduces the production of sebum and shrinks the sebaceous glands. It stabilises keratinization and prevents comedones from forming. It also reduces inflammation in moderate-severe inflammatory acne. The exact mechanism of action is unknown, however it is known that it alters DNA transcription.</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>99.9%</td></tr><tr><th>Metabolism</th><td class="data-table-container"></td></tr><tr><th>Route of elimination</th><td>Isotretinoin and its metabolites are further metabolized into conjugates, which are then excreted in urine and feces. The metabolites of isotretinoin and any conjugates are ultimately excreted in the feces and urine in relatively equal amounts (total of 65% to 83%).</td></tr><tr><th>Half life</th><td>17-50 hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>96 +/- 6.27 L/hr [severe recalcitrant nodular acne pediatric Patients, 12 to 15 Years]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Isotretinoin is teratogenic. It also causes mucocutaneous side effects suck as cheilitis, dry skin, and dry eyes.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9925</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9311</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.7603</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.6144</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8912</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8088</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8639</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8221</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9115</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6025</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9046</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8831</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9301</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9252</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8944
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7081
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Ready biodegradable 
        </td>
        <td>
            0.5554
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.1455 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9562
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9538
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><ul><li>Barr Pharmaceuticals</li>
<li><a href="http://www.catalent.com">Catalent Pharma Solutions</a></li>
<li><a href="http://www.roche.com">F Hoffmann-La Roche Ltd.</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.ranbaxy.com">Ranbaxy Laboratories</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><ul><li><a data-no-turbolink="true" href="/spectra/spectra/nmr_one_d/2037">1H NMR Spectrum</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/2475">MS/MS Spectrum Quattro_QQQ 10</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/2476">MS/MS Spectrum Quattro_QQQ 25</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/2477">MS/MS Spectrum Quattro_QQQ 40</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/nmr_two_d/1971">[1H,13C] 2D NMR Spectrum</a></li></ul></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Isotretinoine decreases the effect of carbamazepine</td></tr><tr><td><a href="/drugs/DB00618">Demeclocycline</a></td><td>Increased risk of intracranial hypertension</td></tr><tr><td><a href="/drugs/DB00254">Doxycycline</a></td><td>Increased risk of intracranial hypertension</td></tr><tr><td><a href="/drugs/DB00931">Methacycline</a></td><td>Increased risk of intracranial hypertension</td></tr><tr><td><a href="/drugs/DB01017">Minocycline</a></td><td>Increased risk of intracranial hypertension</td></tr><tr><td><a href="/drugs/DB00595">Oxytetracycline</a></td><td>Increased risk of intracranial hypertension</td></tr><tr><td><a href="/drugs/DB01301">Rolitetracycline</a></td><td>Increased risk of intracranial hypertension</td></tr><tr><td><a href="/drugs/DB00759">Tetracycline</a></td><td>Increased risk of intracranial hypertension</td></tr><tr><td><a href="/drugs/DB00162">Vitamin A</a></td><td>Isotretinoin increases the risk of vitamin A toxicity. Avoid vitamin A supplementation while taking isotretinoin.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Take with a full glass of water Do not take supplements containing Vitamin A.</li>
<li>Take with high-fat meal to increase absorption.</li></ul></td></tr></tbody></table>